| A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy (NCT07609719) | Genentech, Inc. | 2026-08-17 |
| A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) (NCT07541079) | Genentech, Inc. | 2026-08-15 |
| A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (NCT06984341) | Genentech, Inc. | 2026-06-30 |
| A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT07558915) | Genentech, Inc. | 2026-06-23 |
| A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events (NCT07448038) | Genentech, Inc. | 2026-06-05 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer (NCT07567846) | Genentech, Inc. | 2026-04-29 |
| A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) (NCT07425522) | Genentech, Inc. | 2026-04-21 |
| A Dose-Escalation Study of RO7875913 in Healthy Participants (NCT07342114) | Genentech, Inc. | 2026-03-11 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NCT07214662) | Genentech, Inc. | 2026-01-13 |
| A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants (NCT07329972) | Genentech, Inc. | 2025-11-21 |
| A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants (NCT07214766) | Genentech, Inc. | 2025-10-17 |
| A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis (NCT07008378) | Genentech, Inc. | 2025-10-15 |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer (NCT07100106) | Genentech, Inc. | 2025-10-07 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) (NCT06979336) | Genentech, Inc. | 2025-09-29 |
| A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib (NCT07144111) | Genentech, Inc. | 2025-08-21 |
| A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions (NCT07025577) | Genentech, Inc. | 2025-06-02 |
| A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis (NCT06693908) | Genentech, Inc. | 2025-03-31 |
| A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants (NCT06835465) | Genentech, Inc. | 2025-02-21 |
| A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function (NCT06734208) | Genentech, Inc. | 2025-01-31 |
| A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) (NCT06602453) | Genentech, Inc. | 2025-01-17 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (NCT06488716) | Genentech, Inc. | 2024-12-16 |
| A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease (NCT06603246) | Genentech, Inc. | 2024-11-18 |
| A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants (NCT06690138) | Genentech, Inc. | 2024-11-15 |
| A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors (NCT06619587) | Genentech, Inc. | 2024-11-14 |
| A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants (NCT06677957) | Genentech, Inc. | 2024-11-06 |
| A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors (NCT06372574) | Genentech, Inc. | 2024-09-30 |
| A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period (NCT06524375) | Genentech, Inc. | 2024-08-09 |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis (NCT06096779) | Genentech, Inc. | 2024-07-15 |
| A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects (NCT06462118) | Genentech, Inc. | 2024-06-17 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) (NCT06137183) | Genentech, Inc. | 2024-05-01 |
| Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer (NCT05954871) | Genentech, Inc. | 2024-01-08 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT06031441) | Genentech, Inc. | 2023-11-27 |
| A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC (NCT05968326) | Genentech, Inc. | 2023-10-18 |
| A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (NCT05867121) | Genentech, Inc. | 2023-10-02 |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (NCT05927571) | Genentech, Inc. | 2023-08-10 |
| A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease (NCT05785624) | Genentech, Inc. | 2023-05-26 |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer (NCT05800665) | Genentech, Inc. | 2023-05-02 |
| A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) (NCT05673876) | Genentech, Inc. | 2023-04-06 |
| A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251 (NCT05626114) | Genentech, Inc. | 2023-03-23 |
| A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough (NCT05660850) | Genentech, Inc. | 2023-03-22 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma (NCT05646836) | Genentech, Inc. | 2023-03-21 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis (NCT05462522) | Genentech, Inc. | 2023-01-16 |
| A Study to Characterize Access to Specialty Care Received by American Indians/Alaska Natives (NCT05624788) | Genentech, Inc. | 2022-12-02 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05581004) | Genentech, Inc. | 2022-10-20 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05487235) | Genentech, Inc. | 2022-08-17 |
| A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) (NCT05306340) | Genentech, Inc. | 2022-08-03 |
| A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria (NCT05129423) | Genentech, Inc. | 2022-07-31 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (NCT06850922) | Genentech, Inc. | 2022-06-22 |
| An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration (NCT05300724) | Genentech, Inc. | 2022-05-27 |
| A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema (NCT05224102) | Genentech, Inc. | 2022-02-28 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (NCT05207670) | Genentech, Inc. | 2022-02-01 |
| A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (NCT04853251) | Genentech, Inc. | 2021-12-14 |
| A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications (NCT04353661) | Genentech, Inc. | 2021-11-16 |
| A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (NCT05037929) | Genentech, Inc. | 2021-10-05 |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT04910568) | Genentech, Inc. | 2021-07-26 |
| A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. (NCT04835805) | Genentech, Inc. | 2021-05-13 |
| Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential (NCT04680273) | Genentech, Inc. | 2021-01-07 |
| A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma (NCT04195958) | Genentech, Inc. | 2020-11-30 |
| Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (NCT04539470) | Genentech, Inc. | 2020-11-19 |
| A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT04607148) | Genentech, Inc. | 2020-11-16 |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) (NCT04302025) | Genentech, Inc. | 2020-11-06 |
| Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease (NCT04566003) | Genentech, Inc. | 2020-10-26 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis (NCT04171765) | Genentech, Inc. | 2020-09-30 |
| A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer (NCT04468607) | Genentech, Inc. | 2020-08-31 |
| A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants (NCT04394845) | Genentech, Inc. | 2020-08-11 |
| Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab (NCT04377555) | Genentech, Inc. | 2020-07-30 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (NCT04449874) | Genentech, Inc. | 2020-07-29 |
| A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma (NCT04434469) | Genentech, Inc. | 2020-07-08 |
| A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia (NCT04386616) | Genentech, Inc. | 2020-06-02 |
| A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (NCT04372186) | Genentech, Inc. | 2020-05-14 |
| An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT04250155) | Genentech, Inc. | 2020-03-09 |
| Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential (NCT04274075) | Genentech, Inc. | 2020-03-06 |
| Prospective Clinicogenomic Program (NCT04180176) | Genentech, Inc. | 2019-12-13 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller (NCT04092582) | Genentech, Inc. | 2019-10-31 |
| A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer (NCT03916744) | Genentech, Inc. | 2019-07-26 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT04045028) | Genentech, Inc. | 2019-07-22 |
| A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers. (NCT03961100) | Genentech, Inc. | 2019-06-06 |
| A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) (NCT03972709) | Genentech, Inc. | 2019-06-03 |
| A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases (NCT03858634) | Genentech, Inc. | 2019-05-29 |
| Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis (NCT03816891) | Genentech, Inc. | 2019-03-11 |
| Tenecteplase in Stroke Patients Between 4.5 and 24 Hours (NCT03785678) | Genentech, Inc. | 2019-03-02 |
| A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis (NCT03747575) | Genentech, Inc. | 2019-02-06 |
| A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential (NCT03807739) | Genentech, Inc. | 2019-02-01 |
| A Study of Semorinemab in Patients With Moderate Alzheimer's Disease (NCT03828747) | Genentech, Inc. | 2019-01-25 |
| A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects (NCT03796013) | Genentech, Inc. | 2019-01-10 |
| A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants (NCT03796260) | Genentech, Inc. | 2019-01-09 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC) (NCT03558152) | Genentech, Inc. | 2018-10-26 |
| A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study (NCT03693625) | Genentech, Inc. | 2018-09-27 |
| A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS) (NCT03606460) | Genentech, Inc. | 2018-09-14 |
| A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT03563716) | Genentech, Inc. | 2018-08-10 |
| Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures (NCT03361137) | Genentech, Inc. | 2018-06-28 |
| Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer (NCT03451162) | Genentech, Inc. | 2018-04-17 |
| An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus (NCT03407482) | Genentech, Inc. | 2018-01-09 |
| A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (NCT03289962) | Genentech, Inc. | 2017-12-21 |
| A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants (NCT03381144) | Genentech, Inc. | 2017-12-08 |
| A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (NCT03332797) | Genentech, Inc. | 2017-11-24 |
| A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy (NCT03298516) | Genentech, Inc. | 2017-11-15 |
| A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants (NCT03341884) | Genentech, Inc. | 2017-11-09 |
| A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease (NCT03289143) | Genentech, Inc. | 2017-10-04 |
| Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (NCT03295877) | Genentech, Inc. | 2017-09-21 |